Canaccord Genuity Reiterates a 'Buy' on Amicus Therapeutics (FOLD); Migalastat Ph3 Data Preview

Article Stock Quotes (1) Comments (0)

Canaccord Genuity reiterates a 'Buy' on Amicus Therapeutics (NASDAQ: FOLD) price target of $11.00.

Analyst, Ritu Baral, said, "Reiterate rating and price target on potential positive migalastat pivotal Fabry monoTx data Q3/12, chaperone/ERT comboTx for Fabry, Pompe. We think Q3 pivotal migalastat Fabry monoTx ’011 trial data will be a strong positive catalyst and that the trial has a high chance of success. We also expect positive full Ph2 AT2220/ERT Pompe combo data in Q3/12...We see excellent risk/reward: $5+ upside on success, but only $2-3 downside given floor valuation from comboTx program."

For an analyst ratings summary and ratings history on Amicus Therapeutics click here. For more ratings news on Amicus Therapeutics click here.

Shares of Amicus Therapeutics closed at $5.16 yesterday, with a 52 week range of $2.10-$7.29.

---

Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW

---

*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here

---

---

You May Also Be Interested In

• Canaccord Boosts PT on AcelRx (ACRX) to $11; On Track for Sufentanil NDA Submission by Q313
• Goldman Sachs Downgrades InterXion Holding (INXN) to Neutral
• UBS Raises PT on MEMC (WFR); Thinks Semi Sales Troughed in Q1

Create E-mail Alert Related Categories

Analyst Comments, FDA

Related Entities

Canaccord Genuity

Add Your Comment

Name

Subject

Body

Share on Facebook

Verification
can't see the text?
click here to refresh the image.
what's this?